Evidence map›Paper›PMID 40347464›Full record

ArticleToxicological sciences : an official journal of the Society of Toxicology2025

Perfluorooctane sulfonate exposure and alcohol-associated liver disease severity in a mouse chronic-binge ethanol feeding model.

Frederick A Ekuban, Tyler C Gripshover, Paxton Ames, Kushal Biswas, Oluwanifemi E Bolatimi, Joshua Abramson, Megana Iyer, Jianzhu Luo, Abigail Ekuban, Jae Yeon Hwang and 8 more

Abstract read
In one paragraph

Article in Toxicological sciences : an official journal of the Society of Toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Synergistic toxicity in alcohol-associated liver disease and PFAS exposure.Toxicological sciences : an official journal of the Society of Toxicology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Frederick A EkubanDepartment of Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville, KY 40202, United States.ORCID 0000-0001-7181-7091
Tyler C GripshoverDepartment of Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville, KY 40202, United States.
Paxton AmesDepartment of Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville, KY 40202, United States.
Kushal BiswasDepartment of Biomedical and Nutritional Sciences, University of Massachusetts Lowell, Lowell, MA 01854, United States.
Oluwanifemi E BolatimiDepartment of Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville, KY 40202, United States.
Joshua AbramsonDivision of Gastroenterology, Hepatology and Nutrition, Department of Medicine, School of Medicine, University of Louisville, Louisville, KY 40202, United States.
Megana IyerDivision of Gastroenterology, Hepatology and Nutrition, Department of Medicine, School of Medicine, University of Louisville, Louisville, KY 40202, United States.
Jianzhu LuoDivision of Gastroenterology, Hepatology and Nutrition, Department of Medicine, School of Medicine, University of Louisville, Louisville, KY 40202, United States.
Abigail EkubanDivision of Gastroenterology, Hepatology and Nutrition, Department of Medicine, School of Medicine, University of Louisville, Louisville, KY 40202, United States.
Jae Yeon HwangThe Center for Integrative Environmental Health Sciences Biostatistics and Informatics Facility Core, University of Louisville, Louisville, KY 40202, United States.
Juw Won ParkThe Center for Integrative Environmental Health Sciences Biostatistics and Informatics Facility Core, University of Louisville, Louisville, KY 40202, United States.
Mayukh BanerjeeDepartment of Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville, KY 40202, United States.ORCID 0000-0003-3028-1192
Walter H WatsonDepartment of Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville, KY 40202, United States.
Banrida WahlangDepartment of Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville, KY 40202, United States.
Dhimiter BelloDepartment of Biomedical and Nutritional Sciences, University of Massachusetts Lowell, Lowell, MA 01854, United States.ORCID 0000-0003-2402-5651
Jennifer J SchlezingerDepartment of Environmental Health, Boston University School of Public Health, Boston, MA 02118, United States.ORCID 0000-0001-6834-4369
Craig J McClainDepartment of Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville, KY 40202, United States.
Matthew C CaveDepartment of Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville, KY 40202, United States.

Funding

WKU Lead Faculty AwardP20GM103436 · NIGMS · UNIVERSITY OF LOUISVILLE · PI Bruce A Mattingly · 2012 to 2026
$60.1M
Role of oxidized linoleic acid metabolites in the pathogenesis of alcoholic liver diseaseP20GM113226 · NIGMS · UNIVERSITY OF LOUISVILLE · PI BARVE, SHIRISH S · 2016 to 2025
$24.1M
Superfund Training CoreP42ES023716 · NIEHS · UNIVERSITY OF LOUISVILLE · PI SRIVASTAVA, SANJAY · 2017 to 2025
$18.1M
The Role of Nutrition in the Development/Progression of Alcohol-Induced Organ InjuryP50AA024337 · NIAAA · UNIVERSITY OF LOUISVILLE · PI Xiang Zhang · 2016 to 2026
$17.9M
University of Louisville Center for Integrative Environmental Health SciencesP30ES030283 · NIEHS · UNIVERSITY OF LOUISVILLE · PI Amanda Jo LeBlanc · 2020 to 2026
$10.0M
UOFL ENVIRONMENTAL HEALTH SCIENCES TRAINING PROGRAMT32ES011564 · NIEHS · UNIVERSITY OF LOUISVILLE · PI David W Hein, John Pierce Wise · 2004 to 2026
$7.1M
Environmental Liver DiseaseR35ES028373 · NIEHS · UNIVERSITY OF LOUISVILLE · PI CAVE, MATTHEW C · 2017 to 2024
$4.0M
Exposome and Precision Medicine in NAFLDR01ES032189 · NIEHS · UNIVERSITY OF LOUISVILLE · PI CAVE, MATTHEW C · 2020 to 2022
$1.9M
Evaluating mechanisms of sex differences in environmentally-induced metabolic diseasesK01ES033289 · NIEHS · UNIVERSITY OF LOUISVILLE · PI WAHLANG, BANRIDA · 2022 to 2024
$448k
DoD TERP HT9425-23-1-0690FEMA DHS EMW-2020-FP-00078National Institutes of Environmental Health Sciences K01ES033289National Institutes of Environmental Health Sciences P30ES030283National Institutes of Environmental Health Sciences P42ES023716National Institutes of Environmental Health Sciences R01ES032189National Institutes of Environmental Health Sciences R35ES028373National Institutes of Environmental Health Sciences T32ES011564NIAAA NIH HHS P50 AA024337NIAAA NIH HHS P50AA024337NIEHS NIH HHS K01 ES033289NIEHS NIH HHS P30 ES030283NIEHS NIH HHS P42 ES023716NIEHS NIH HHS R01 ES032189NIEHS NIH HHS R35 ES028373NIEHS NIH HHS T32 ES011564NIGMS NIH HHS P20 GM103436NIGMS NIH HHS P20GM103436NIGMS NIH HHS P20 GM113226NIGMS NIH HHS P20GM113226
6 · The paper itself

Abstract

Exposure to pollutants, including the ubiquitous "forever chemical," perfluorooctane sulfonate (PFOS) has increasingly been associated with metabolic dysfunction-associated steatotic liver disease. Recent epidemiological evidence has identified associations between per- and polyfluoroalkyl substances (PFAS) exposure and increased liver injury in alcohol consumers, suggesting potential interactions between these exposures. However, the intersection of pollutant exposures and alcohol-associated liver disease (ALD) is not well studied. We hypothesize that pollutants may disrupt hepatic metabolism to modify ALD severity. Recently, we developed a two-hit (ethanol [EtOH] plus pollutant) mouse model, enabling testing of this hypothesis. Here, we elucidate the metabolic and disease-modifying effects of PFOS in this model. Male C57BL/6J mice were fed isocaloric control or 5% EtOH Lieber-DeCarli diet for 15 days. From day 6 of feeding, mice were concurrently gavaged with 1 mg/kg PFOS or 2% tween-80 vehicle for 10 days, followed by a 5 g/kg EtOH binge dose and euthanized 5 to 6 h later. Approximately 60% of the administered PFOS dose accumulated in the liver. PFOS exacerbated EtOH-induced hepatic steatosis and was associated by higher levels of plasma very low-density lipoprotein and alanine aminotransferase. PFOS upregulated hepatic EtOH-metabolizing enzymes and lowered blood alcohol levels. Ingenuity Pathway Analysis (IPA) Top Toxicity Functions/Lists associated with hepatic gene expression following PFOS co-exposure in EtOH-fed mice included: Fatty acid metabolism and liver steatosis; nuclear receptor activation, cytochrome P450, and reactive oxygen species; apoptosis; liver fibrosis; and hepatocellular carcinoma (HCC). Gene Ontology/Kyoto Encyclopedia of Genes and Genomes analyses similarly revealed enrichment in fatty acid, xenobiotic, alcohol, or glutathione metabolic processes; and peroxisome proliferator-activated receptor (PPAR) signaling. PFOS upregulated hepatic expression of several nuclear receptors (e.g. Pparα, Car, and Pxr) and their P450 target genes (e.g. Cyp4a10, Cyp2b10, and Cyp3a11) by real-time-PCR or Western blot, confirming key IPA predictions. PFOS is a metabolism-disrupting chemical that worsens ALD severity. PFOS activated hepatic nuclear receptors and enriched hepatic transcriptional pathways associated with steatosis, xenobiotic metabolism, oxidative stress, cell death, fibrosis, and HCC. These data demonstrate a novel mechanism whereby PFOS exacerbates ALD through coordinated dysregulation of lipid homeostasis and liver injury, potentially mediated by nuclear receptor activation. The identification of PFOS as an ALD risk modifier highlights the critical need to evaluate environmental pollutants as potential contributors to liver disease progression. More data are required on environmental pollution as a disease-modifying factor in ALD. Impact Statement: The present study demonstrates that PFOS exacerbates alcohol-induced liver injury through nuclear receptor activation and metabolic disruption. These findings provide novel insights into how environmental pollutants can act as significant risk modifiers in ALD, how PFAS exposures may contribute to the growing public health burden of liver disease, and underscore the importance of considering combined risk factors in developing targeted interventions.

Indexed as

Alkanesulfonic AcidsBinge DrinkingEthanolFluorocarbonsLiverLiver Diseases, AlcoholicAnimalsDisease Models, AnimalMaleMiceMice, Inbred C57BLSeverity of Illness IndexAlkanesulfonic AcidsEthanolFluorocarbonsperfluorooctane sulfonic acidalcohol-associated liver diseaseethanollipid metabolismnuclear receptor activationperfluorooctane sulfonatetranscriptomics

Identifiers

PMID40347464
PMCPMC12329793

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.